According to the CRO, this strategic partnership comes at a ‘pivotal’ time as the UK government emphasizes the importance of innovative, multi-sector collaboration.
The partnership between Ora and the NWL Clinical Trials Alliance aims to support this initiative by bringing together academia, industry and the NHS to provide ‘better solutions’ that will address the gap in patient-access to cutting-edge treatment options.
For sponsors planning or considering trial delivery in Europe, the collaboration will provide ‘comprehensive’ analysis of country and site selection, including feedback based on 'open and honest communication' with study sites.
In addition, it will offer access to a diverse group of study participants, as well as ‘operational excellence’ delivered by a seasoned team of ophthalmology-focused resources.
Stuart Abelson, CEO of Ora, said: “Ora and the NWL Clinical Trials Alliance share a common goal: improve access to, and the quality of, clinical research in Europe.”
“Ora’s well-established leadership position in ophthalmology research, coupled with the reach and relationships established by the NWL Clinical Trials Alliance, will provide our sponsors with an increased level of confidence to deliver European-based early and late-phase research studies.”
Dr Suki Balendra, director of North West London Clinical Trials Alliance, added: “We are honoured to partner with a globally recognized leader in ophthalmology research.”
“Collaborating with Ora not only improves outcomes for historically underrepresented patient populations but provides an opportunity to explore new and innovative ways to increase clinical trial access for all patients. Europe is in a position to accelerate getting drugs to market faster, while simultaneously helping to build a robust and sustainable clinical research ecosystem beyond the US.”